Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03423160 · ClinicalTrials.gov registry record

A Novel Framework for Impaired Imitation in ASD

A clinical trial of Autism Spectrum Disorder, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

Active
Registry status
201
Enrollment target
1
Study location

NCT03423160: Active study of Autism Spectrum Disorder, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

NCT03423160 is a study of Autism Spectrum Disorder that is active but no longer recruiting, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 201 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (50% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03423160, a study of Autism Spectrum Disorder, is active but no longer recruiting, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

ACTIVE NOT RECRUITING
Registry status
201 participants
Enrollment target
1
Study location

Study Summary

There is long-standing recognition that people with autism spectrum disorders (ASD) have difficulty imitating others' actions; some investigators have highlighted impaired imitation as being a core contributor to the development of autism. What is yet unknown is precisely how imitation in children with ASD differs from that of typically developing peers.The investigators have identified a task parameter that separates preserved from impaired gesture imitation in ASD: children with ASD have difficulty imitating when the task requires two separate movement elements be coordinated simultaneously. By contrast, imitation is relatively preserved when movement elements are performed serially. The coordination of simultaneous movements is a hallmark of actions performed in the real world. With an eye to optimizing common therapies that depend heavily on imitation, the next step is to tease apart where, in the chain from perception to action, the capacity limitation in simultaneous processing lies. This study will be conducted in about two days and will involve imitating gestures that are presented via video. In addition, an EEG will record the brain's electrical activity during certain tasks to assess how the brain responds when the imitation task is more or less difficult. Several other clinical and behavioral measures will also be used.

Primary Outcome

2-3 purpose-designed psychophysical measures of gesture imitation ability and its sub-components

Conditions Studied

Interventions

  • OTHER None--observational

Study Locations (1)

Maryland

  • Kennedy Krieger Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2018-04-24
Est. Completion 2025-12-31

What the registry record for NCT03423160 still lists

NCT03423160 is an observational study that tracks outcomes without assigning an intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (50% higher).

The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which None--observational is the first listed.

NCT03423160 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03423160 about?

NCT03423160 is a clinical study titled "A Novel Framework for Impaired Imitation in ASD". There is long-standing recognition that people with autism spectrum disorders (ASD) have difficulty imitating others' actions; some investigators have highlighted impaired imitation as being a core contributor to the development of autism. What is yet unknown is precisely how imitation in children w...

What is the current status of trial NCT03423160?

This trial is currently active not recruiting. The enrollment target is 201 participants. The study started on 2018-04-24. Estimated completion is 2025-12-31.

What conditions does trial NCT03423160 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder.

What interventions are being tested in trial NCT03423160?

The interventions under investigation include: None--observational (OTHER).

Who is sponsoring clinical trial NCT03423160?

This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03423160 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03423160's enrollment target sits among peer trials

201 38th of 224 higher than 187 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03423160, the US trial registry maintained by the National Library of Medicine. NCT03423160 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.